Table 5.
LC/ESI/MS Results of Peptide Cross-links Formed by DCVCS (+158.9990 Da) or NA-DCVCS (+201.0096 Da) after Dosing Rats
| (A) 230 μmol/kg DCVCS
| |||||
|---|---|---|---|---|---|
| cross-linked peptides | masstheo (Da) | massobs (Da) | cross-linker | modified position | na |
| α1 (12–40)b + β1 (83–95)c | 4813.1678 | 4813.2031 | NA-DCVCS | Cys13+Cys93 | 2/3 |
| α1 (8–31)b + β1 (67–95)c | 6070.6264 | 6070.8096 | NA-DCVCS | Cys13+Cys93 | |
| α1 (100–127)b + β1 (121–132)c | 4605.1559 | 4606.2055 | NA-DCVCS | Cys104/111+Cys125 | 3/3 |
| α1 (93–127)b + β1 (121–132)c | 5401.5388 | 5401.7339 | NA-DCVCS | Cys104/111+Cys125 | |
| α1 (12–16)b + α1 (12–31)b | 2926.2547 | 2926.1982 | DCVCS | Cys13+Cys13 | 2/3 |
| α1 (12–16)b + α1 (12–40)b | 3962.7493 | 3962.5723 | NA-DCVCS | Cys13+Cys13 | |
| α1 (12–31)b + α2 (1–16) | 4108.9050 | 4108.7754 | NA-DCVCS | Cys13+Cys13 | |
| β1 (83–95)c + β1 (83–104)c | 4180.9156 | 4180.8003 | DCVCS | Cys93+Cys93 | 2/3 |
| β1 (77–95)c + β1 (67–95)c | 5585.7246 | 5585.7383 | DCVCS | Cys93+Cys93 | |
| β1 (105–132)c + β1 (105–132)c | 6229.2571 | 6229.2702 | DCVCS | Cys125+Cys125 | 2/3 |
| β1 (121–132)c + β1 (105–132)c | 4537.2160 | 4536.2302 | DCVCS | Cys125+Cys125 | |
| β1 (121–144)c + β1 (121–144)c | 5088.5520 | 5088.7539 | NA-DCVCS | Cys125+Cys125 | |
| β1 (77–104)c + β1 (105–132)c | 6479.2471 | 6479.2661 | DCVCS | Cys93+Cys125 | 2/3 |
| β1 (67–95)c + β1 (121–146)c | 6194.0462 | 6193.8677 | NA-DCVCS | Cys93+Cys125 | |
| β1 (77–95)c + α1 (100–127)b | 5397.5616 | 5397.4292 | DCVCS | Cys93+Cys104/111 | 1/3 |
| α1 (8–16)b + α1 (100–127)b | 4478.0209 | 4477.7983 | DCVCS | Cys13+Cys104/111 | 2/3 |
| α2 (1–16) + α1 (93–127)b | 5812.6036 | 5812.8316 | NA-DCVCS | Cys13+Cys104/111 | 1/3 |
| α1 (12–31)b + β1 (105–132)c | 5396.6212 | 5396.7607 | NA-DCVCS | Cys13+Cys125 | |
|
| |||||
|
(B) 23 μmol/kg DCVCS
| |||||
| α1 (12–16)b + β1 (67–95)c | 4014.9141 | 4015.1177 | DCVCS | Cys13+Cys93 | 3/4 |
| α1 (1–16) + β1 (77–104)c | 5235.5290 | 5235.6445 | DCVCS | Cys13+Cys93 | |
| α1 (8–16)b + β1 (83–104)c | 3828.7668 | 3828.9341 | NA-DCVCS | Cys13+Cys93 | |
| α2 (1–16) + β1 (83–95)c | 3407.7036 | 3406.6116 | NA-DCVCS | Cys13+Cys93 | |
| α1 (100–127)b + β1 (121–144)c | 5705.7610 | 5705.7770 | NA-DCVCS | Cys104/111+Cys125 | 1/4 |
| α1 (1–16) + α2 (1–16) | 3697.8228 | 3697.9409 | DCVCS | Cys13+Cys13 | 1/4 |
| β1 (83–95)c + β1 (83–104)c | 4180.9156 | 4180.1304 | DCVCS | Cys93+Cys93 | 1/4 |
| β1 (77–104)c + β1 (83–104)c | 6008.8536 | 6009.0044 | DCVCS | Cys93+Cys93 | |
| β1 (121–144)c + β1 (121–144)2 | 5088.5520 | 5088.7450 | NA-DCVCS | Cys125+Cys125 | 1/4 |
| β1 (83–104)c+ β1 (105–132)c | 5800.8636 | 5800.8906 | NA-DCVCS | Cys93+Cys125 | 1/4 |
| β1 (67–95)c + α1 (100–127)b | 4478.0209 | 4477.7983 | DCVCS | Cys93+Cys104/111 | 1/4 |
a
n=number of rats detected with cross-link over total number of rats.
b
Peptides α1 (8–16), (8–31), (12–16), (12–31), (12–40), (93–127), and (100–127) can also be from α2.
c
Peptides β1 (67–95), (77–95), (77–104), (83–95), (83–104), (105–132), (121–132), (121–144), and (121–146) can also be from β2.